Maria Brink1, Anders Green2, Anders Bo Bojesen3, J Steve Lamberti4, Yeates Conwell5, Kjeld Andersen6. 1. Research Unit of Psychiatry, Institute of Clinical Research, University of Southern Denmark, Sdr. Boulevard 29, 5000 Odense C, Denmark. Electronic address: maria.brink@rsyd.dk. 2. Odense Patient data Explorative Network, OPEN, OUH Odense University Hospital & SDU University of Southern Denmark, J. B. Winsløws Vej 9A, 3th Floor, DK-5000 Odense C, Denmark. 3. Mental Health Services in the Region of Southern Denmark, Odense, Denmark. 4. Department of Psychiatry, University of Rochester Medical Center, Rochester, 14642, NY, USA. 5. Office for Aging Research and Health Services, Geriatric Psychiatry Program and Schizophrenia Treatment Research Laboratory, University of Rochester Medical Center (URMC), 300 Crittenden Blvd., Rochester, 14642, NY, USA. 6. Research Unit of Psychiatry, Institute of Clinical Research, University of Southern Denmark, Sdr. Boulevard 29, 5000 Odense C, Denmark.
Abstract
INTRODUCTION: People with severe mental illness have greater risk of un-detected and inadequately treated medical disorders, adding up to the risk of premature death. This study investigated how chronic medical comorbidity evolved across the lifespan in schizophrenia and the associated impact on mortality. METHOD: A register-based retrospective nested case-control study was conducted, identifying incident cases of cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), cancer and diabetes, as well as mortality due to these diseases, across the lifespan in schizophrenia. SAMPLE: A schizophrenia cohort consisting of 4924 individuals aged 18-40 years registered with a diagnosis of schizophrenia (ICD-8: 295.0-3 + 295.9) during admission to a psychiatric hospital unit in 1970-79. Schizophrenia cases were age and gender matched with 22,597 controls in the general population. RESULTS: Rate ratio (RR) of CVD and cancer were similar to controls. The RR of COPD and diabetes were increased across the lifespan. The probability of having been diagnosed prior to dying from CVD, cancer, pulmonary diseases or diabetes was markedly reduced in schizophrenia cases compared to controls. The RR of all-cause mortality and mortality from CVD, COPD and diabetes remained elevated in all age groups in schizophrenia. Registration of medical comorbidity was associated with increased survival. CONCLUSION: Excess medical comorbidity persists across the lifespan and into older age. No age-related decrease in incidence of major chronic medical comorbidities in schizophrenia was found except for diabetes.
INTRODUCTION:People with severe mental illness have greater risk of un-detected and inadequately treated medical disorders, adding up to the risk of premature death. This study investigated how chronic medical comorbidity evolved across the lifespan in schizophrenia and the associated impact on mortality. METHOD: A register-based retrospective nested case-control study was conducted, identifying incident cases of cardiovascular disease (CVD), chronic obstructive pulmonary disease (COPD), cancer and diabetes, as well as mortality due to these diseases, across the lifespan in schizophrenia. SAMPLE: A schizophrenia cohort consisting of 4924 individuals aged 18-40 years registered with a diagnosis of schizophrenia (ICD-8: 295.0-3 + 295.9) during admission to a psychiatric hospital unit in 1970-79. Schizophrenia cases were age and gender matched with 22,597 controls in the general population. RESULTS: Rate ratio (RR) of CVD and cancer were similar to controls. The RR of COPD and diabetes were increased across the lifespan. The probability of having been diagnosed prior to dying from CVD, cancer, pulmonary diseases or diabetes was markedly reduced in schizophrenia cases compared to controls. The RR of all-cause mortality and mortality from CVD, COPD and diabetes remained elevated in all age groups in schizophrenia. Registration of medical comorbidity was associated with increased survival. CONCLUSION: Excess medical comorbidity persists across the lifespan and into older age. No age-related decrease in incidence of major chronic medical comorbidities in schizophrenia was found except for diabetes.
Authors: Inmaculada Guerrero Fernández de Alba; Antonio Gimeno-Miguel; Beatriz Poblador-Plou; Luis Andrés Gimeno-Feliu; Ignatios Ioakeim-Skoufa; Gemma Rojo-Martínez; Maria João Forjaz; Alexandra Prados-Torres Journal: Sci Rep Date: 2020-11-11 Impact factor: 4.379
Authors: Kaare Christensen; Mary K Wojczynski; Jacob K Pedersen; Lisbeth A Larsen; Susanne Kløjgaard; Axel Skytthe; Matt McGue; James W Vaupel; Michael A Province Journal: Aging Cell Date: 2020-09-04 Impact factor: 9.304
Authors: Eleonora Gatta; Vikram Saudagar; Jenny Drnevich; Marc P Forrest; James Auta; Lindsay V Clark; Henry Sershen; Robert C Smith; Dennis R Grayson; John M Davis; Alessandro Guidotti Journal: Schizophr Bull Open Date: 2021-02-06
Authors: Kristina Edvardsson; Elizabeth Hughes; Beverley Copnell; Ingrid Mogren; Don Vicendese; Richard Gray Journal: PLoS One Date: 2022-02-28 Impact factor: 3.240